Amgen Inc
AMGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$415.00 | Kjpw | Fmfpbsxng |
Maintaining Our $260 Amgen FVE Following in Line Q1, Despite Expanding Tax Dispute
Amgen's first-quarter 6% total revenue growth (2% product sales growth) and 15% non-GAAP EPS growth put the firm on track to meet our forecast for the year, and we're not making any significant changes to our $260 fair value estimate for the firm.